STW:PA:PA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 235.75

Change

-1.70 (-0.72)%

Market Cap

USD 0.82B

Volume

3.45K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.60 (-1.30%)

USD 61.43B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-2.30 (-0.45%)

USD 12.30B
WRD:PA HSBC ETFs Public Limited Compa..

-0.16 (-0.47%)

USD 9.84B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-1.19 (-0.49%)

USD 8.53B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-2.20 (-0.51%)

USD 7.74B
HHH:PA HSBC ETFs Public Limited Compa..

-0.22 (-0.43%)

USD 6.87B
WLD:PA Lyxor UCITS MSCI World D-EUR

-1.62 (-0.49%)

USD 6.71B
LCWD:PA Multi Units Luxembourg - Lyxor..

-0.09 (-0.53%)

USD 6.16B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-1.63 (-0.45%)

USD 4.86B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

-0.61 (-0.42%)

USD 4.57B

ETFs Containing STW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.43% 87% B+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.43% 86% B+ 83% B
Trailing 12 Months  
Capital Gain 13.83% 55% F 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.83% 50% F 67% D+
Trailing 5 Years  
Capital Gain 60.48% 73% C 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.48% 72% C 75% C
Average Annual (5 Year Horizon)  
Capital Gain 8.53% 59% D- 61% D-
Dividend Return 8.53% 65% D 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.33% 69% C- 85% B
Risk Adjusted Return 102.47% 98% N/A 96% N/A
Market Capitalization 0.82B 78% C+ 78% C+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike